CG Invites Co., Ltd. Logo

CG Invites Co., Ltd.

Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.

083790 | KO

Overview

Corporate Details

ISIN(s):
KR7083790006
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로 38 마곡동, 강서구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized precision medicine. Leveraging its core competency in developing novel chemical and biological drugs—such as Acelex (osteoarthritis), Ivaltinostat (pancreatic cancer), and Camrelizumab (immuno-oncology)—the company has expanded its focus to several key areas. These include whole genome sequencing, contributing to large-scale bio-data projects; the development of personalized, mRNA-based cancer vaccines targeting tumor-specific neoantigens; and digital therapeutics (DTx), exemplified by its HealthOnG platform for diabetes management. The company's strategy is to innovate within the digital genome market by integrating its drug development expertise with cutting-edge genomic and digital health technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-14 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 34.7 KB
2025-08-08 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.7 MB
2025-07-25 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 16.5 KB
2025-07-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-07-10 00:00
Legal Proceedings Report
소송등의판결ㆍ결정 (신주발행 무효-취하)
Korean 5.3 KB
2025-07-10 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 38.0 KB
2025-07-01 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 14.1 KB
2025-07-01 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-06-05 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 134.5 KB
2025-06-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.6 KB
2025-06-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 29.4 KB
2025-06-05 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.8 MB

Automate Your Workflow. Get a real-time feed of all CG Invites Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CG Invites Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CG Invites Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.